SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

 

 

Filed by the Registrant o

 

Filed by a Party other than the Registrant x

 

Check the appropriate box:

 

o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o Definitive Proxy Statement
o Definitive Additional Materials
x Soliciting Material Under Rule 14a-12

 

AMAG PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

 

Caligan Partners LP

Caligan Partners CV II LP

David Johnson

Samuel J. Merksamer

Paul Fonteyne

Lisa Gersh

Kenneth Shea

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

 

 
 

 

Payment of Filing Fee (check the appropriate box):

 

x No fee required.
   
o Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.

 

  1) Title of each class of securities to which transaction applies:
     
     
     
  2) Aggregate number of securities to which transaction applies:
     
     

 

  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     
     
  4) Proposed maximum aggregate value of transaction:
     
     
     
  5) Total fee paid:
     
     
     

 

o Fee paid previously with preliminary materials.

 

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

  1) Amount Previously Paid:
     
     
     
  2) Form, Schedule or Registration Statement No.:
     
     
     
  3) Filing Party:
     
     
     
  4) Date Filed:

 

 
 

On September 4, 2019, Caligan Partners LP (“Caligan”) issued a press release (the “Press Release”) and made available a presentation (the “Presentation”) on the website www.saveamag.com (the “Website”) to stockholders of AMAG Pharmaceuticals, Inc. (“AMAG”). A copy of each of the Press Release, the Presentation and the Website is attached herewith as Exhibit 1, Exhibit 2 and Exhibit 3, respectively.

In addition, Caligan filed a Schedule 13D/A containing additional information regarding Caligan’s intention to solicit the consents of stockholders of AMAG, the relevant text of which is attached herewith as Exhibit 4.

 
 

 

Exhibit 1

CALIGAN PARTNERS FILES PRELIMINARY CONSENT STATEMENT TO REPLACE FOUR DIRECTORS OF AMAG PHARMACEUTICALS, INC.

CALIGAN RELEASES PRESENTATION AT WWW.SAVEAMAG.COM DETAILING URGENT NEED FOR CHANGE

NEW YORK, September 4, 2019— Caligan Partners LP (“Caligan”), one of the largest shareholders of AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”), announced today that it has filed a preliminary consent statement with the U.S. Securities and Exchange Commission (the “SEC”) for shareholders to act by written consent to effect the replacement of four directors of AMAG and to, among other things, amend the Company's bylaws to help prevent against entrenchment by incumbent directors.

Caligan’s nominees for change include:

·Paul Fonteyne, former CEO of Boehringer Ingelheim USA
·Lisa Gersh, former CEO of Alexander Wang, Goop, and Martha Stewart Living Omnimedia
·David Johnson, Managing Partner of Caligan Partners LP
·Kenneth Shea, Senior Advisor, Guggenheim Securities, LLC

Additional information on each of the nominees is available at www.saveamag.com. Caligan has released presentation materials highlighting the operational, strategic, and capital allocation missteps that have resulted in over $1.3 billion of value destruction overseen by AMAG’s incumbent board and management. The materials note that while Caligan believes AMAG has unique, durable assets that could be worth at least $30 per share, AMAG’s current leadership will be unable to achieve that outcome for shareholders. The presentation can be accessed here.

David Johnson, Managing Partner of Caligan, issued the following statement: “We believe urgent change is needed at AMAG to reverse the sharp share price decline caused by the Company’s misguided strategic priorities. Caligan’s highly qualified nominees will conduct a comprehensive review of AMAG’s product portfolio, research and development priorities, and SG&A spending.”

Once Caligan files a definitive consent statement, Caligan will begin soliciting the consents of stockholders.

Caligan strongly recommends that if AMAG stockholders have loaned, pledged or hypothecated any of their Common Stock, they consult with their bank or broker in order to have these shares returned to their accounts before the forthcoming record date. Doing so will allow AMAG stockholders to express consent on all of their shares of Common Stock in favor of Caligan’s nominees and proposals.

Investor Contact

Edward McCarthy/ Geoffrey Weinberg

DF King & Co., Inc.

+1 (212) 269-5550

AMAG@dfking.com

 

Media Contact

Robert Laman

Caligan Partners

+1 (646) 859-8205

rl@caliganpartners.com

 

For Additional Information

IR@caliganpartners.com

 

LEGEND

Caligan, Caligan CV II LP, David Johnson, Samuel Merksamer, Paul Fonteyne, Lisa Gersh, and Kenneth Shea (collectively, the “Participants”) intend to file with the SEC a definitive consent statement and accompanying form of consent card to be used in connection with the solicitation of consents from the stockholders of AMAG Pharmaceuticals, Inc. (the “Company”). All stockholders of the Company are advised to read the definitive consent statement and other documents related to the solicitation of consents by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive consent statement and an accompanying consent card will be furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/ and at Caligan’s website www.saveamag.com and from the Participants’ consent solicitor, D.F. King & Co., Inc. by requesting a copy via email to AMAG@dfking.com. Information about the Participants and a description of their direct or indirect interests by security holdings is contained in the Schedule 14A filed by Caligan with the SEC on September 4, 2019. This document is available free of charge from the sources indicated above.

About Caligan Partners LP

Caligan Partners LP is an investment firm headquartered in New York, NY that pursues a deep value-oriented strategy through investments in activist equities and distressed debt.

 
 

 

Exhibit 2

SAVING AMAG: URGENT CHANGE NEEDED TO UNLOCK VALUE SEPTEMBER 2019 WWW.SAVEAMAG.COM

 
 

Additional Information 2 • THIS PRESENTATION AND THE VIEWS EXPRESSED HEREIN ARE ONLY TO BE USED TO PROVIDE GENERAL INFORMATION FROM CALIGAN PARTNERS LP AND ITS AFFILIATES (COLLECTIVELY, “CALIGAN”) REGARDING AMAG PHARMACEUTICALS, INC . (“AMAG” OR THE “COMPANY”) . THIS PRESENTATION AND THE VIEWS EXPRESSED HEREIN DO NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVICE ON THE MERITS OF ANY INVESTMENT DECISION . THE VIEWS EXPRESSED HEREIN REPRESENT THE CURRENT OPINIONS AS OF THE DATE HEREOF OF CALIGAN AND ARE DERIVED FROM PUBLICLY AVAILABLE INFORMATION AND THE ANALYSIS OF CALIGAN REGARDING THE COMPANY . CERTAIN FINANCIAL INFORMATION AND DATA USED HEREIN HAVE BEEN DERIVED OR OBTAINED FROM, WITHOUT INDEPENDENT VERIFICATION, PUBLIC FILINGS, INCLUDING FILINGS MADE BY THE COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION (“SEC”), AND OTHER SOURCES . • THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY DESCRIBED HEREIN IN ANY JURISDICTION TO ANY PERSON, NOR DOES IT CONSTITUTE A FINANCIAL PROMOTION, INVESTMENT ADVICE OR AN INDUCEMENT OR AN INCITEMENT TO PARTICIPATE IN ANY PRODUCT, OFFERING OR INVESTMENT . THIS PRESENTATION IS INFORMATIONAL ONLY AND SHOULD NOT BE USED AS THE BASIS FOR ANY INVESTMENT DECISION, NOR SHOULD IT BE RELIED UPON FOR LEGAL, ACCOUNTING OR TAX ADVICE OR INVESTMENT RECOMMENDATIONS OR FOR ANY OTHER PURPOSE . NO REPRESENTATION OR WARRANTY IS MADE THAT CALIGAN’S INVESTMENT PROCESSES OR INVESTMENT OBJECTIVES WILL OR ARE LIKELY TO BE ACHIEVED OR SUCCESSFUL OR THAT CALIGAN’S INVESTMENT WILL MAKE ANY PROFIT OR WILL NOT SUSTAIN LOSSES . PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS . • CALIGAN HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION INDICATED HEREIN AS HAVING BEEN OBTAINED OR DERIVED FROM STATEMENTS MADE OR PUBLISHED BY THIRD PARTIES . ANY SUCH STATEMENTS OR INFORMATION SHOULD NOT BE VIEWED AS INDICATING THE SUPPORT OF SUCH THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN . NO WARRANTY IS MADE THAT DATA OR INFORMATION, WHETHER DERIVED OR OBTAINED FROM FILINGS MADE WITH THE SEC OR FROM ANY THIRD PARTY, ARE ACCURATE . • EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE MATTERS ADDRESSED IN THIS PRESENTATION, INCLUDING PROJECTIONS, MARKET OUTLOOKS, ASSUMPTIONS AND ESTIMATES, ARE FORWARD - LOOKING STATEMENTS THAT ARE BASED ON CERTAIN ASSUMPTIONS, AND INVOLVE CERTAIN RISKS AND UNCERTAINTIES, INCLUDING RISKS AND CHANGES AFFECTING INDUSTRIES GENERALLY AND THE COMPANY SPECIFICALLY . YOU SHOULD BE AWARE THAT PROJECTIONS AND OTHER FORWARD - LOOKING STATEMENTS ARE INHERENTLY UNCERTAIN, AND ACTUAL RESULTS MAY DIFFER FROM THE PROJECTIONS AND OTHER FORWARD LOOKING STATEMENTS CONTAINED HEREIN DUE TO REASONS THAT MAY OR MAY NOT BE FORESEEABLE . NO REPRESENTATION, WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS MADE AS TO THE ACCURACY OR REASONABLENESS OF THE ASSUMPTIONS UNDERLYING THE PROJECTIONS AND OTHER FORWARD LOOKING STATEMENTS CONTAINED HEREIN OR TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION OR VIEWS CONTAINED HEREIN . • CALIGAN SHALL NOT BE RESPONSIBLE OR HAVE ANY LIABILITY FOR ANY MISINFORMATION CONTAINED IN ANY SEC FILING, ANY THIRD PARTY REPORT OR THIS PRESENTATION . ALL AMOUNTS, MARKET VALUE INFORMATION AND ESTIMATES INCLUDED IN THIS PRESENTATION HAVE BEEN OBTAINED FROM OUTSIDE SOURCES THAT CALIGAN BELIEVES TO BE RELIABLE OR REPRESENT THE BEST JUDGMENT OF CALIGAN AS OF THE DATE OF THIS PRESENTATION . • CALIGAN RESERVES THE RIGHT TO CHANGE OR MODIFY ANY OF ITS OPINIONS EXPRESSED HEREIN AT ANY TIME AS IT DEEMS APPROPRIATE . CALIGAN DISCLAIMS ANY OBLIGATION TO UPDATE THE INFORMATION CONTAINED HEREIN .

 
 

Executive Summary 3 • Caligan Partners, LP is one of the largest shareholders of AMAG Pharmaceuticals, owning over 10 % of AMAG’s outstanding shares • Caligan is seeking removal of four incumbent AMAG directors who have seen an average total shareholder return of NEGATIVE 63 . 9 % 2 over their tenures • Caligan’s has nominated four individuals (the “Nominees”) who will bring the experience, financial discipline, and accountability necessary to rebuild shareholder value • Caligan believes that AMAG could be worth more than $ 30 per share 1 , 170 % higher than its current trading levels 1 See slide 6 for additional details. Based on AMAG’s closing share price of $11.24 as of September 3, 2019 2 See slide 12 for additional details

 
 

Caligan’s Message to AMAG Shareholders • Caligan is seeking your support to : • Remove four AMAG directors who have overseen significant value destruction • Elect our four highly qualified Nominees to the Board • To prevent Board entrenchment, Caligan is asking your consent to : • Repeal any provision in the bylaws that would seek to circumvent our attempts to act by written consent • Amend the bylaws to fix the size of the Board at nine members and require unanimous approval in order for the Board to amend the bylaws • To ensure you have the right to consent : • If you have loaned, pledged, or hypothecated your common stock, please consult with your bank or broker in order to have those shares returned to your account before the record date (which we expect to be set by AMAG) 4

 
 

Caligan Nominees For Change 5 Nominees Education Relevant Experience Paul Fonteyne MBA, Carnegie Mellon University MS, Chemical Engineering, University of Brussels • President and CEO of Boehringer Ingelheim USA Corporation • Commercial Leadership Roles, Boehringer Ingelheim, Merck and Co., Inc. and Abbott Laboratories • Current Director of resTORbio , Inc. (TORC) and Ypsomed Holding AG (SWX: YPSN) Lisa Gersh JD, Rutgers Law School BA, SUNY Binghamton • Former CEO, Alexander Wang, Former CEO, Goop Inc. • President & CEO, Martha Stewart Living Omnimedia • Current Director of Hasbro, Inc. (HAS) and Establishment Labs Holdings, Inc. (ESTA) David Johnson SM, Harvard College AB, Harvard College • Co - Founder, Managing Partner, Caligan Partners LP • Former Managing Director, The Carlyle Group • Former Vice President, Morgan Stanley Kenneth Shea MBA, University of Virginia BA, Boston College • Senior Advisor, Guggenheim Securities, LLC • Former Senior Managing Director, Guggenheim Securities • Former Senior Managing Director, Bear, Stearns & Co. Inc. • Current Director of Equity Commonwealth (EQC)

 
 

What Could AMAG Be Worth? 6 1 S&P Capital IQ For Consensus Revenue estimates and highest analyst revenue estimates 2 Caligan estimates . High end of the EV/Revenue range consistent with Vifor Pharma EV/Revenue multiple as detailed on slide 17 . For Feraheme International Rights, 26 % global market share on $ 413 MM of ex - US Ferinject sales equals $ 119 MM of ex - US Feraheme revenue . At a 33 . 33 % royalty rate, AMAG would receive $ 39 . 7 MM annually . 3 - 7 x capitalization rate . 3 Caligan calculation based on AMAG 2018 10 - K which disclosed $ 46 . 9 MM of tax - effected net operating losses, $ 24 . 3 MM of tax credit carryforwards, $ 20 . 9 MM of tax - effected capital loss carryforwards, and Caligan’s estimate of $ 165 MM of 2019 pre - tax operating losses multiplied by a 21 % effective tax rate 4 Value of AMAG’s pipeline assets is based on AMAG capital invested to date, including $ 68 . 2 MM for the acquisition of Perosphere , $ 22 . 5 MM for the acquisition of Velo Bio LLC, and $ 100 MM of investment in R&D in 2019 5 Caligan fully - diluted share calculation based on RSUs outstanding, options outstanding, and conversion of the 2022 convertible notes 6 Based on AMAG’s closing price of $ 11 . 24 on September 3 , 2019 • Caligan believes the individual pieces of AMAG’s portfolio are worth substantially more than AMAG’s current enterprise value • A strategic review could maximize value for AMAG shareholders by unlocking its significant sum of the parts discount • Caligan believes that, assuming conservative EV/revenue multiples and ascribing no value to AMAG’s pipeline, AMAG is worth at least ~ $ 30 per share, a 170 % premium to current trading levels Base High 2020E Feraheme Revenues 1 186.1 210.0 EV/Revenue 2 3.0x 7.0x Feraheme EV 558.2 1,470.0 Feraheme International Rights 2 119.1 277.9 2020E Makena Revenues 1 111.5 156.9 EV/Revenue 2 2.0x 3.0x Makena EV 223.0 470.7 Other Products 1 54.9 75.4 EV/Revenue 2 1.0x 2.0x Other Products EV 54.9 150.8 Tax Assets 3 126.7 126.7 Pipeline Assets 4 190.7 190.7 Total AMAG EV 1,272.6 2,686.8 YE2019 Net (Debt)/Cash 1 200.0 200.0 Total Equity Value 1,472.6 2,886.8 Fully Diluted Shares Outstanding 5 48.6 49.4 AMAG Value Per Share 30.31$ 58.42$ Upside 6 170% 420%

 
 

AMAG Has a Collection of Valuable Assets 7 • Feraheme is a one of two approved high molecular weight IV irons in the US ; 2019 E net sales of $ 170 MM 1 • Feraheme has competitive advantages (substantially lower rates of hypophosphatemia, lower cost per dose) versus its primary competitor, Injectafer • AMAG owns the worldwide rights to Feraheme but has no international distribution partner currently • Makena is the only FDA approved therapy indicated to reduce the risk of recurrent pre - term birth ; 2019 E net sales of ~ $ 145 MM 1 1 Consensus estimates from S&P Capital IQ.

 
 

Feraheme Is A Durable, Growing Product 8 • Feraheme is one of six marketed intravenous (IV) iron products in the US and one of two high molecular weight IV irons • Feraheme received a label expansion in February 2018 , based on a non - inferiority study versus Injectafer, which allowed it to expand into iron deficiency anemia (IDA) in non - chronic kidney disease (non - CKD) patients, resulting in revenue growth of 27 % in 2018 and consensus revenue growth of 26 % in 2019 . The non - inferiority study highlighted Feraheme’s (i) comparable safety profile and (ii) hypophosphatemia benefits versus Injectafer • IV irons are non - biologic complex drugs (“NBCD”) ; Venofer’s patents expired in November 2003 and it has not had a generic competitor introduced to date Marketed US IV Iron Revenue Per Product ($MM) 1 1 Consensus estimates for revenue and revenue growth from S&P Capital IQ 0 50 100 150 200 250 300 350 400 450 500 Ferrlecit InFed Nulecit Feraheme Venofer Injectafer 2019E Growth 1 : 0% 0% 0% 26% - 3% 18% Patent Expiry: Expired Expired N/A 2023 Expired 2003 2027 Approved: 1999 1974 2011 2009 2000 2013

 
 

Feraheme & Makena Auto - Injector Continue To Grow Market Share 9 • Post label expansion in February 2018 , Feraheme has continued to increase its share of the IDA market . Caligan believes that, given the hypophosphatemia and cost benefits versus Injectafer , Feraheme has a significant opportunity to grow its presence in gastroenterology, oncology, and iron deficiency in pregnancy • Makena, the only FDA approved treatment option to lower the risk of recurrent preterm birth, has had generic competition since July 2018 . AMAG launched its patent - protected auto - injector in 2 Q 2018 and has continued to take share from the generic intramuscular injection due to physician, nurse and patient preference for the auto - injector • Caligan believes Feraheme and Makena are durable, growing products which serve serious medical needs and could make AMAG worth ~ $ 30 /share 3 . AMAG’s Board and management have chosen to invest the cash flows from Feraheme and Makena in value destructive business development Feraheme IDA Market Share 1 Makena Auto - Injector Market Share 2 1 AMAG Quarterly Investor Presentations 2 AMAG Quarterly Investor Presentations. Share of FDA - approved hydroxyprogesterone caproate 3 See slide 6 for additional details 10% 11% 12% 13% 14% 15% 16% 17% 18% 1Q2018 2Q2018 3Q2018 4Q2018 1Q2019 2Q2019 Post IDA non - CKD label expansion 10% 20% 30% 40% 50% 60% 70% 4Q2018 1Q2019 2Q2019

 
 

Fundamental Problems At AMAG 10 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

Underperformance Of Total Shareholder Return Over Any Time Period Against Any Relevant Benchmark 11 • AMAG has materially underperformed all of its relevant benchmarks over the last 1 , 2 , 3 , 5 and 10 - year periods • Specifically, AMAG has underperformed the NASDAQ Biotech Index by : • - 393 % over the last 10 years • - 84 % over the last 5 years 1 Through July 31, 2019, the day before Caligan began substantial purchases of AMAG shares. All TSR data from S&P Capital IQ 2 Proxy peers include ACOR, ASRT, EGRX, EBS, HZNP, IRWD, NKTR, PCRX, SPPI, SUPN, MDCO, TXMD, and VNDA 10-Yr 1 5-Year 1 3-Year 1 2-Year 1 1-Year 1 AMAG Pharmaceuticals -81.8% -56.7% -68.9% -57.9% -62.5% Nasdaq Biotech Index 310.9% 27.4% 10.2% -1.1% -9.2% Relative Performance -392.7% -84.1% -79.1% -56.7% -53.3% Proxy Peer Average 2 112.3% 61.1% 0.4% -8.0% -32.7% Relative Performance -194.1% -117.9% -69.3% -49.9% -29.9% Proxy Peer Median 2 14.7% -3.8% 10.3% -6.7% -37.0% Relative Performance -96.5% -52.9% -79.2% -51.2% -25.6% Russell 2000 224.5% 50.7% 34.4% 13.0% -4.5% Relative Performance -306.3% -107.4% -103.2% -70.9% -58.1%

 
 

Significant Underperformance Over The Course Of Every Director’s Tenure 1 12 • AMAG’s total shareholder return has significantly underperformed both the Nasdaq Biotech Index and the S&P 500 over the tenure of every director • Every AMAG director has overseen a significant absolute decline in AMAG shares over their tenure 1 Through July 31, 2019, the day before Caligan began substantial purchases of AMAG shares. All TSR data from S&P Capital IQ Directors for which Caligan is seeking their removal Director Director Since AMAG Performance Nasdaq Biotech Index AMAG Relative Performance S&P 500 AMAG Relative Performance Davey Scoon 12/1/2006 -86.0% 307.3% -393.3% 175.4% -261.4% Gino Santini 2/7/2012 -51.1% 165.7% -216.8% 156.4% -207.6% Bill Heiden 5/9/2012 -48.4% 160.3% -208.8% 153.5% -202.0% Barbara Deptula 9/9/2013 -66.9% 55.6% -122.4% 99.8% -166.6% James Sulat 4/16/2014 -53.5% 43.7% -97.1% 77.3% -130.8% Dr. John Fallon 9/5/2014 -64.8% 18.1% -82.9% 63.3% -128.1% Rob Perez 7/1/2015 -88.3% -13.7% -74.7% 55.2% -143.5% Kathrine O'Brien 4/12/2019 -33.9% -4.8% -29.1% 3.0% -36.9% Anne Phillips 4/12/2019 -33.9% -4.8% -29.1% 3.0% -36.9%

 
 

-100% -50% 0% 50% 100% 150% 200% 250% 300% 350% 400% Underperformance Versus Peer Set 1 13 • Relative to its 2013 and 2018 proxy peer sets, AMAG is the third and second worst performing company in the peer group, respectively • To note, 7 of the 18 companies in the 2013 proxy peer set have sold themselves • From May 9 , 2012 to July 31 , 2019 , AMAG has underperformed : • The 2013 Peer Group by - 186 % • The 2018 Peer Group by - 150 % 1 Total shareholder return performance from May 9, 2012, the day of the appointment of Bill Heiden as CEO, through July 31, 2019, the day before Caligan began substantial purchases of AMAG shares. Peer Group’s from AMAG Proxy Statements. 2012 Proxy Peer Group not disclosed. AMAG has underperformed every proxy peer set over every year from 2013 – 2018. All TSR data from S&P Capital IQ TSR (2013 Proxy Peer Group) 1 TSR (2018 Proxy Peer Group) 2 -100% 200% 500% 800% 1100% 1400% 1700% 2000% 2300% 2600% DYAX RGEN ARRY LGND ALNY NPSP CADX IMMU SCMP ENZN DUSA OPTR ASRT PGNX AMAG INFI AFFY

 
 

Fundamental Problems At AMAG 14 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

Over $1.3 Billion Of Non - Feraheme Capital Invested Since 2013 Has Resulted In Negative Value To AMAG Shareholders 15 • $ 1 . 38 Bn of shareholder capital has been spent on non - Feraheme related R&D, acquisitions (net of divestitures), and milestone payments from Jan 2012 – June 2019 . The cumulative change in AMAG’s market cap since May 2012 is negative $ 13 MM . 1 All information from AMAG SEC filings. Non - Feraheme R&D is R&D enumerated in AMAG SEC filings to products other than Feraheme. Acquisitions are netted with the proceeds of the CBR sale. Milestone payments includes the $60MM payment to Palatin that was paid in July 2019. Change in AMAG market capitaliza tio n from S&P Capital IQ. Capital Invested vs Change in Market Cap (May 2012 – July 2019) 1 (50) 100 250 400 550 700 850 1,000 1,150 1,300 1,450 2012 - 2019 Capital Invested Change in Mkt Cap (Since May 2012) Non-Feraheme R&D Acquisitions (Net) Milestone Payments Total

 
 

Despite 27% CAGR For Feraheme Sales, AMAG’s Market Cap Has Declined At A 1% CAGR 16 • Despite AMAG’s only commercial product in 2012 , Feraheme, growing its US revenues at a 27 % CAGR from 2012 – 2019 E, AMAG’s market capitalization has declined at a 1 % CAGR since May 2012 • Additionally, due to the dilution from value destructive stock issuances, AMAG shareholders who held AMAG stock in 2012 only own 63 % of Feraheme today • Based on our analysis, if, beginning in 2012 , AMAG had done no business development and AMAG traded at the same multiple of forward revenues that it did in 2012 , AMAG’s market cap would be at least 52 % higher than where it is trading today 3 1 All market capitalization data from S&P Capital IQ 2 SEC Filings 3 AMAG traded at 1.57x forward revenues in March 2012. Using 1.57x EV/Revenues multiplied by $170MM of 2019E Revenues for Fera he me, excluding the 37% share dilution would imply a market capitalization of $423MM, a 52% premium to AMAG’s $278MM market capitalization as of July 31, 2019 AMAG Market Cap 1 Feraheme US Net Revenues 2 275 277 279 281 283 285 287 289 291 293 AMAG Mkt Cap - May 2012 AMAG Mkt Cap - July 2019 - 1% CAGR 50 70 90 110 130 150 170 190 2012 2019E 27% CAGR

 
 

- 2,000 4,000 6,000 8,000 10,000 12,000 Vifor IV Iron 2019E Rev Vifor EV - July 2019 - 50 100 150 200 250 300 350 Feraheme 2019E Rev AMAG EV - July 2019 Comparison With Vifor Highlights Undervalued IV Iron Franchise 17 • Feraheme, despite having no international distribution partner, and giving a four year head start to Injectafer to penetrate IDA in non - CKD patients in the US, is on pace to generate $ 170 MM of revenue in 2019 . As physician awareness of Feraheme’s benefits increases, Caligan believes Feraheme will continue to grow its share of the IDA market • Despite a growing, durable, IV iron franchise, AMAG trades at a fraction of the multiple of Vifor Pharma, the dominant IV iron competitor • We believe that separating Feraheme from the rest of AMAG should deliver significant value to AMAG shareholders that is multiples higher than its current trading price 1 Consensus Feraheme estimates from S&P Capital IQ. EV from S&P Capital IQ 2 Consensus IV iron estimates from S&P Capital IQ. EV from S&P Capital IQ. Vifor IV Iron revenue incorporates the full amount o f Regent’s US sales. Vifor reports 33.3% of the total revenue for Regent’s sales and bears no costs. AMAG ( Feraheme ) ($MM) 1 Vifor Pharma ($MM) 2 1.7x EV/Revenue 7.5x EV/Revenue

 
 

• For public companies focused on women’s health, despite having the highest 2020 E consensus revenue, AMAG has (i) a lower enterprise value than both TherapeuticsMD and Obseva and (ii) the worst TSR of the three companies under the tenure of AMAG’s current Board and management • Caligan believes this disconnect between commercial success and market value results from (i) a lack of management credibility with the investment community ; (ii) poor capital allocation ; and (iii) the market’s view of AMAG’s pipeline Comparison With Other Women’s Health Companies Demonstrates Market’s Opinion of AMAG Board, Management, & Pipeline 18 1 S&P Capital IQ consensus estimates 2 S&P Capital IQ as of 7 / 31 / 19 , , the day before Caligan began substantial purchases of AMAG shares 3 All TSR data from S&P Capital IQ . Obseva TSR from IPO as of January 25 , 2017 2020 Consensus Revenue ($MM) 1 Current Enterprise Value 2 TSR Since May 2012 3 - 50 100 150 200 250 300 350 400 AMAG TXMD OBSV - 50 100 150 200 250 300 350 400 450 500 TXMD OBSV AMAG -50% -45% -40% -35% -30% -25% -20% -15% -10% -5% 0% TXMD OBSV AMAG

 
 

Fundamental Problems At AMAG 19 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

• As a percentage of revenues, AMAG’s cash SG&A spending is 30 percentage points higher than its next closest peer and 50 percentage points higher than pharmaceutical companies with similar product revenues • AMAG spends more than 90 % of its market capitalization on its commercial infrastructure and launch costs . The next closest peer is 50 percentage points lower and AMAG is 80 percentage points higher than the average of pharmaceutical companies with similar product revenues • This spending, associated with Intrarosa and Vyleesi launches and commercialization, is a significant overhang on AMAG shares with the investment community AMAG’s Commercial Infrastructure And Launch Costs Are Exorbitant Relative To Peers 3 20 1 SG&A is last quarter SG&A reported in respective SEC filings, less stock - based compensation expense, annualized . 2020 E revenues are consensus estimates from S&P Capital IQ . Comparison set is chosen as US public pharmaceutical and biotech companies that are expected to generate between $ 300 MM and $ 600 MM of product revenue in 2020 . 2 SG&A is last quarter SG&A reported in respective SEC filings, less stock - based compensation expense, annualized . Market Capitalization calculated by S&P Capital IQ . Comparison set is chosen as US public pharmaceutical and biotech companies that are expected to generate between $ 300 MM and $ 600 MM of consensus product revenue in 2020 . 3 Comparison set is chosen as US public pharmaceutical and biotech companies that are expected to generate between $ 300 MM and $ 600 MM of consensus product revenue in 2020 . SG&A Run - Rate (% of 2020E Revenues) 1 SG&A Run - Rate (% of Market Cap) 2 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

 
 

• The synergies that AMAG highlighted when pursuing the Lumara and CBR acquisitions have never materialized : • When announcing the Lumara acquisition in September 2014 , AMAG highlighted revenues of $ 180 MM and EBITDA of $ 110 MM and synergies of $ 20 MM . Combined with Feraheme this would imply an operating expense run - rate of $ 101 MM . Actual 2015 operating expense of $ 131 MM missed by over $ 30 MM • Then, in 2015 , in announcing the purchase of CBR, AMAG highlighted $ 60 MM of EBITDA from CBR, which included $ 15 MM of synergies . Combined with Feraheme and Makena, this implied an operating expense run - rate of $ 145 MM . Actual 2016 operating expense of $ 193 MM missed by over $ 47 MM Announced Merger Synergies Never Materialized 21 1 Feraheme 2014 SG&A is from AMAG”s 10 - Q annualized . Makena operating expenses are calculated as $ 180 MM of revenue at an assumed 95 % gross margin less $ 110 MM of EBITDA . Synergies are from AMAG’s investor presentation announcing the acquisition . 2015 Actual is from AMAG’s 2018 10 - K 2 Feraheme 2014 SG&A is from AMAG”s 10 - Q annualized . Makena operating expenses are calculated as $ 180 MM of revenue at an assumed 95 % gross margin less $ 110 MM of EBITDA . Synergies are from AMAG’s investor presentation announcing the acquisition . CBR operating expenses are using AMAG”s projections from the CBR acquisition announcement which assumed $ 120 MM of revenue, at a 95 % gross margin, less $ 60 MM of EBITDA . 2016 Actual operating expenses are from AMAG’s 2016 10 - K Feraheme + Makena Opex ($MM) 1 Feraheme, Makena + CBR Opex ($MM) 2 $30MM Miss $47MM Miss

 
 

AMAG SG&A Productivity Lowest Of Peers With >$300MM Product Revenue 22 1 Gross Profit and SG&A from 2014 – 2018 from SEC Filings (S&P Capital IQ). AMAG Gross Profit excludes intangible amortization. Peer group selected as companies with >$300MM of product revenue in 2015 and consensus estimates of >$300MM of product revenue in 2019E 5 - Year Gross Profit/SG&A Ratio 1 • Of all North American biotech and pharmaceutical companies that generated more than $ 300 MM of revenue in 2015 and have consensus revenue estimates of more than $ 300 MM of revenue for 2019 , AMAG has the lowest SG&A productivity with a ratio that’s half of the peer average • Caligan believes this poor productivity results from disparate commercial infrastructure for its women’s health and nephrology portfolio and sub - scale product offerings 0x 1x 2x 3x 4x 5x 6x 7x 5-Year GP/SG&A Avg

 
 

AMAG’s Women’s Health Sales Force Productivity Is Poor • While the productivity of AMAG’s sales representatives that are dedicated to Feraheme is in - line with pharmaceutical and biotech company averages, the productivity of AMAG’s sales representatives focused on women’s health (post - AMAG’s sales force consolidation in 1 Q 2019 ) is worst - in - class • Caligan believes that this poor productivity results from (i) a sub - scale product portfolio ; (ii) a lack of adjustment in Makena dedicated personnel post - generic entry ; (iii) poor performance of Intrarosa ; and (iv) a lack of management discipline with commercial spending 1 Peer group selected as US pharmaceutical and biotech companies with > $200MM of product revenue in 2018 for which the number of sales and marketing employees is disclosed in the respective company’s 10 - K. Consensus revenues estimates from S&P Capital IQ. Employee data from SEC Filings 23 2019E Revenues/Sales Employee ($MM) 1 - 1 2 3 4 5 6 7 8 9 10 AKRX INCY CELG ALXN AMAG - Fer. UTHR CHRS PTCT AGN IRWD ACAD AMAG - WH BHC Revenue/Sales Employee Average

 
 

Pipeline & Spending Remain Overhang With Investment Community 24 Analyst Date Jefferies May 7 , 2019 “It is hard to be encouraged by the potential of the pipeline when AMAG narratives have repeatedly failed to pan out . Currently trading at ~ 1 x 2019 revenue, its valuation largely reflects the Street's disappointment/concerns . ” JP Morgan May 8 , 2019 “Heading into a period of increased R&D spend and continued investment in Intrarosa coupled with anticipated launch spend for Vyleesi for which we and the market have significant market questions , we think investors will need to see demonstrated traction in driving revenues from these assets (and/or surprises from the pipeline) for the stock to outperform . ” Piper Jaffray May 22 , 2019 “We don’t doubt that AMAG’s recent delevering was the right move but continue to question if FY 19 's ~ $ 150 M+ y/y negative EBITDA swing to support Intrarosa and Vyleesi is wise . ” – May 22 , 2019 Leerink June 23 , 2019 “We believe that commercial potential of Vylessi remains an outstanding debate given its route of administration via injection and risks around market creation . ” Piper Jaffray June 24 , 2019 “We still think the drug’s profile ( SubQ injection at least 45 minutes prior to anticipated sexual activity, with a 40 % nausea rate and ~ 5 % vomiting rate) makes for a difficult sell . Combining this with a history of disappointing launches ( MuGard , Intrarosa to name two), we think a wait and see approach is warranted here . ” HC Wainwright August 1 , 2019 “AMAG shares have declined consistently since peaking in July 2015 , with shares down 89 % versus the healthcare XLV up 20 % .... The CBR business failed to live up to management’s expectations . Likewise, the company’s acquisition of Intrarosa has been another disappointment . ” Cowen August 7 , 2019 “ As for our broader thesis – and as we have indicated in the past and above – we simply do not believe in the current new commercial portfolio (Intrarosa and Vyleesi) , and with Makena stalled, this leaves Faraheme as the lone growth driver . At this valuation that is simply not enough . Although management is indicating that the company should be EBITDA neutral next year, given our likely lower total sales expectations for the company, we believe the losses will persist into 2021 . And again, given our view of high development risk for AMAG - 423 and ciraparantag, we believe investors should seek better options . ” Source: Analyst reports. Permission to use quotations neither sought nor obtained.

 
 

Fundamental Problems At AMAG 25 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

AMAG Management Has Consistently Missed Expectations 26 Product Public Statement 2019E Revenues 1 MuGard “In terms of product potential, there are estimated to be around 400 , 000 patients each year who’re at risk of developing oral mucositis, so it's a fairly significant market and using numbers like a 5 % share of that market opportunity would bring in revenues of excess of $ 20 million . ” – William Heiden, Morgan Stanley Conference, September 9 , 2017 N/M Makena “ So here we are in 2017 with forecasted sales of Makena of approximately $ 425 million at the middle of our range . Now we have a range of cases in our scenario planning for 2020 . Our base case assumptions include the sub - q auto - injector is approved in the fourth quarter of 2017 and generics to the intramuscular product arrive to the market in February 2018 . You can see here that our Makena sales by 2020 in that base or middle case scenario ( $ 250 MM) , which include an authorized generic and some net price decline on the branded Makena business due to generic entries may be lower in 2020 than in 2017 . So that's the base case . ” – William Heiden, 2017 Analyst Day, May 24 , 2017 “So no, that isn't changed . Remember that wasn't guidance . That was sort of directional discussion . ” – Edward Myles, 3 Q 2017 Earnings Call, November 2 , 2017 $145MM Cord Blood Registry “We believe our purchase price represents an attractive valuation for this profitable business at approximately 11 x expected 2015 adjusted EBITDA, including cost synergies . And with some of the revenue synergy opportunities for the future, we like the valuation even more . ” – Frank Thomas, M&A Call, June 29 , 2015 Divested for $170MM Loss in June 2018 (56% of AMAG EV) Intrarosa “ As you move down the income statement to adjusted EBITDA, you'll see that we are planning to invest significantly in Intrarosa in 2017 . As Nik mentioned, we believe this product is a significant revenue opportunity, potentially exceeding $ 500 million per year . ” – Edward Myles, 1 Q 2017 Earnings Call, May 2 , 2017 $20MM Source: S&P Capital IQ transcripts 1 Consensus Expectations

 
 

Long - Term “Credibility” Gap • Setting and consistently meeting expectations is essential to building trust with the investment community . AMAG’s missed expectations on every product acquisition have completely eroded analyst confidence in AMAG forecasts . There is a $ 216 MM gap between consensus and AMAG’s Analyst Day 2022 revenue forecast 1 2019 Analyst Day projections estimated by Caligan from slide 48 and consensus from S&P Capital IQ as of September 3, 2019 27 Guidance vs Consensus 1 300 350 400 450 500 550 600 650 700 2019 2020 2021 2022 2019 Analyst Day Projected US Revenues Consensus $216MM Gap Between Guidance & Consensus

 
 

Short - Term “Credibility” Gap • Even on a short - term basis, the market’s consensus revenue estimates for AMAG are lower than AMAG’s low - end of its guidance range, the 2 nd lowest for any biotech or pharmaceutical company with at least $ 300 MM of consensus revenue estimates . This delta highlights what little credence the investment community gives to AMAG’s forecasts . 1 S&P Capital IQ as of September 3, 2019. Companies with >$300MM of estimated revenue and >$300MM market capitalization 28 Consensus Revenue Less Low - End of Company Revenue Guidance ($MM) 1 (50) - 50 100 150 200 250 300

 
 

0x 1x 2x 3x 4x 5x 6x 7x 8x PTCT NTRA HARV IRWD CHRS SUPN PCRX CORT TSX:ADVZ AMPH PAHC LCI AKRX OPK AMAG AMAG Trades At Lowest EV/Revenue Multiple Of Biotech and Pharmaceutical Companies With Greater Than $300MM of Revenue 29 1 TEV < $2.5Bn; Estimated Forward Product Revenues > $300MM as of July 31, 2019 the day before Caligan began substantial purcha se s of AMAG shares EV/2019 Revenue 1

 
 

Fundamental Problems At AMAG 30 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

AMAG’s Public Statements Confirm No Portfolio Synergies 31 Product Public Statement Makena “And so, large sales force, about 110 reps out there , calling on the OB/GYNs . Very good, sort of stickiness within the supply chain and reimbursement channel . Good connections to the payers . ” – Ed Myles, BAML Leveraged Finance Conference, November 29 , 2016 Intrarosa “As we look at the 150 approximately sales folks bearing down, this is a competitive marketplace . There are other folks out there who will have sales forces . And making sure that we're getting the appropriate share of voice across all of the target physicians is going to be important, not just OB/GYNs but also looking at high - prescribing primary care physicians in some cases, who are also prescribing in this field . ” – Nicholas Grund, 4 Q 2016 Earnings Call, February 14 , 2017 Vyleesi “Frankly, it's a little bit too early to tell, right? So as we go through the final budget planning and go - to - market strategy, a lot of it is around where do women present . As you know, this condition is -- struggles with low awareness at the physician level on diagnosis pathways . So some women with the condition are ending up at OB/GYNs, where we're very very, strong in both maternal health and Intrarosa sales forces, but also some end up in sexual health experts as well as psychiatrists or psychologists . So making sure that we know exactly where patients are presenting is an important part of how we go to market . ” - Nicholas Grund, 3 Q 2018 Earnings Call, November 1 , 2018 Feraheme “ On the Feraheme side, again, I think we're looking for profitable growth on Feraheme . So we took a responsible approach at expanding into additional segments, primarily GIs . We also have an effort in OB/GYN, that's not going away, but this expansion was primarily about getting some broader reach into the GI marketplace . It's a modest increase . We went from roughly 42 to roughly 48 , but we also have a very talented team out there, and strategic account managers, they're almost solely dedicated to hematology, oncology space, doing some contracting with those groups and then also in the hospital setting . ” - Anthony Casciano, 1 Q 2019 Earnings Call, May 7 , 2019 Source: S&P Capital IQ transcripts • Despite consolidation of the Makena and Intrarosa sales forces announced on 4 Q 2018 earnings call, AMAG has publicly communicated that they expect SG&A to increase in 2019 with increased investment in direct - to - consumer campaign spending ; further highlighting the lack of commercial synergies across their portfolio

 
 

- 100 200 300 400 500 600 - 50 100 150 200 250 300 350 2015 2016 2017 2018 2019E Revenues ($MM) Cash SG&A ($MM) Compensation & Benefits Professional, Consulting, Other Outside Revenues AMAG’s Disparate Therapeutic Portfolio Provides No Leverage On Existing Commercial Infrastructure • To launch Intrarosa and Vyleesi, AMAG has increased its SG&A by $ 165 MM from 2016 to 2019 during a period when revenues declined ~ $ 100 MM overall . Caligan believes it is unlikely that AMAG shareholders will see any return on this spending 32 AMAG Cash SG&A vs Revenues 1 1 AMAG SEC Filings. 2015 SG&A breakdown between professional and consulting and compensation and benefits is a Caligan estimat e, though the aggregate number is from AMAG’s 2019 10 - K $165MM More SG&A In 2019 vs 2016

 
 

Fundamental Problems At AMAG 33 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan

 
 

34 Action Rationale Significant Board Refreshment • Given AMAG’s absolute and relative underperformance, AMAG would benefit from the fresh perspective of a new set of independent directors that includes both (i) directors with significant pharmaceutical expertise and public company experience and (ii) direct representation for AMAG shareholders • Caligan is proposing 4 new directors, 3 independent of Caligan Comprehensive Review of Strategic Alternatives • Post board refreshment, AMAG should conduct a comprehensive review of strategic alternatives of its asset portfolio • The nephrology, women’s health, and hematology assets cannot leverage a single commercial infrastructure (or require additional direct - to - consumer marketing spending that questions the need for a sales force) questioning the logic of having multiple subscale therapeutic focuses Immediate Rationalization of Commercial Footprint to Achieve Positive EBITDA • Given the spending and pipeline overhang with the investment community, the quickest way to re - build trust is to immediately get the company to profitability • Positive steps include exploring non - traditional ways and partnerships to monetize Intrarosa and Vyleesi and establishing risk - sharing development partnerships on ciraparantag and AMAG - 423 that alleviate the R&D burden on AMAG Monetize Feraheme International Rights • Given the hypophosphatemia benefits vs . Injectafer that the non - inferiority study demonstrated, this would seem like an opportune time to explore a new partnership (Vifor/Daiichi provides a template) • A low - risk business development initiative could provide substantial upside to AMAG shareholders Caligan Action Plan

 
 

AMAG Directors Have Purchased an Immaterial Number of Shares 1 35 • AMAG’s directors own an immaterial amount of shares (< 0 . 50 % ) and, over the last 7 years, only one director has purchased shares worth ~ $ 100 k . Caligan owns over 10 % of AMAG’s shares . • As AMAG shareholders have lost ~ 50 % of their share value under current leadership, annual director compensation (retainer, RSUs, and options) has increased at a 28 % CAGR 1 SEC Form 3 & 4 Filings as of May 20, 2019 for Independent Directors. John Fallon purchased 3,230 shares on November 10, 2015 f or $31.20 per share. 2 As disclosed in AMAG annual proxy statements Director Ownership Of AMAG (% O/S) 1 Annual Director Compensation 2 0% 2% 4% 6% 8% 10% 12% Director Shares Purchased Director Shares Owned Caligan - 50,000 100,000 150,000 200,000 250,000 2012 2013 2014 2015 2016 2017 2018 Cash RSU Options 28% CAGR

 
 

AMAG Board Should Explore Whether Separating Assets Will Create Value 36 1 Consensus estimates 2 Caligan estimates 3 1Q2019 Earnings Call 4 2Q2018 Earnings Call; pre - sales force consolidation Nephrology/Hematology Women’s Health Feraheme Pipeline 2019E Revenues 1 $170MM N/A 2019E EBITDA 2 $100MM $(50)MM Worldwide Rights Yes Yes Sales Reps 3 48 N/A Sales Points Hematologists Oncologists GPOs Gastroenterologists Hospitals Hematologists Hospitals Potential Indications Patient Blood Management Heart Failure Iron Deficiency Anticoagulant reversal Makena Intrarosa / Vyleesi Pipeline 2019E Revenues 1 $145MM $20MM N/A 2019E EBITDA 2 $50MM $(130)MM $(50)MM Worldwide Rights Yes No Yes Sales Reps 4 105 137 N/A Sales Points OB/GYNs OB/GYNs SH Experts Psychiatrists Psychologists OB/GYNs Hospitals Potential Indications N/A Intrarosa for HSDD Severe preeclampsia Separating AMAG assets could create shareholder value

 
 

SG&A Should Be Reduced Immediately 37 1 Consensus revenue estimates. SG&A is last quarter annualized. Best - In - Class is Amphastar Pharmaceuticals. Peer Average is US public pharmaceutical and biotech companies that are expected to generate between $300MM and $600MM of product revenue in 2020 2 Excluding CBR. SG&A from AMAG 2016 10 - K SG&A Run - Rate (% of 2020E Revenues) 1 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% AMAG (Current) AMAG (2016) Peer Average "Best-In-Class" • In 2016 , when AMAG’s only commercial products were Feraheme and Makena, AMAG spent $ 128 MM on SG&A ( 30 % of revenue) 2 • In 2019 , AMAG is on pace to spend more than 85 % of revenues on SG&A : • Peer Average = 34 . 2 % • Best - In - Class = 12 . 8 % • Applying average SG&A % of sales generates $ 172 MM of cost savings • Applying best - in - class SG&A % of sales generates $ 248 MM of cost savings • AMAG is spending $ 165 MM in SG&A to generate an incremental $ 20 MM in revenue from Intrarosa and Vylessi . This needs to be stopped immediately

 
 

AMAG Needs An International Distribution Partner For Feraheme 38 1 S&P Capital IQ For Consensus Estimates 2 26% global market share on $413MM of ex - US Ferinject sales equals $119MM of ex - US Feraheme revenue. At a 33.33% royalty rate, AMAG would receive $39.7MM annually. At a 3x – 7x capitalization rate, AMAG’s market capitalization would increase by $119MM – $278MM, 33 - 77% higher than its closing market capit alization of $362MM on September 3, 2019. Ferinject vs. Feraheme ex - US Revenues 1 - 50 100 150 200 250 300 350 400 450 500 Ferinject ROW 2019E Revenues Feraheme ROW 2019E Revenues • Ferinject (the ex - US brand name for Injectafer ) consensus estimates are for over $ 450 MM of international revenue in 2019 • Ferinject is launching in Japan this year . On its 1 H 2019 earnings call, Vifor estimated ~ 5 million patients in Japan are suffering from iron deficiency anemia with more than 50 % of them not being treated at all and less than 10 % are currently being treated with intravenous iron • Caligan (and Vifor ) believes there is a huge unmet medical need in treating iron deficiency and iron deficiency anemia worldwide . Vifor has observed 25 % + volume growth in underpenetrated therapy areas, such as cardiology and patient blood management in Europe and oncology and gastroenterology in the U . S . • Regent (a subsidiary of Daiichi) pays Vifor a 33 . 33 % revenue royalty on its sales of Venofer and Injectafer in the US and bears all of the costs of marketing • If Feraheme achieved similar market share penetration in the rest of the world as it did in the US, Feraheme could achieve over $ 100 MM of international revenues . At a 33 % royalty rate and a 5 x capitalization multiple, getting an international distribution partner for Feraheme could increase AMAG’s share price by 33 % - 77 % 2

 
 

Caligan’s Research on AMAG Pharmaceuticals • Caligan has conducted exhaustive research over the past 18 months to better understand AMAG’s products and strategy, including working with respected former pharmaceutical executives to diligence each of AMAG’s products • Caligan has worked with leading nephrologists, chemists, and academics to understand the potential of Feraheme in the US and internationally and its competitive advantages versus other IV irons • Caligan has spoken to OB/GYNs, lead investigators, and consultants to evaluate AMAG’s women’s health assets and its current commercial strategy • Our conclusion from this analysis is that AMAG’s assets are valuable/durable and that the business possesses several fundamental upside drivers but that its future will be increasingly difficult if AMAG continues with its existing strategy • Caligan believes that AMAG needs ( i ) board refreshment to reestablish credibility with the investment community and (ii) to implement some low - risk, high reward value creation initiatives 39

 
 

About Caligan Partners 40 Caligan Partners, LP was founded by David Johnson and Sam Merksamer in 2017 to pursue a deep value - oriented investment strategy Caligan’s principals have extensive experience working closely with management teams on strategic and operating initiatives, and working through industry transitions to create value Caligan matches its investment horizon to the opportunity, with a singular focus on creating value for its investors and shareholders

 
 

Contacts & Additional Information 41 Investors Edward McCarthy/ Geoffrey Weinberg D . F . King & Co . , Inc . + 1 ( 212 ) 269 - 5550 AMAG@dfking . com Press Robert Laman Caligan Partners + 1 ( 646 ) 859 - 8205 rl@caliganpartners . com F or Additional Information IR@caliganpartners . com LEGEND Caligan, Caligan CV II LP, David Johnson, Samuel Merksamer, Paul Fonteyne, Lisa Gersh , and Kenneth Shea (collectively, the “Participants”) intend to file with the SEC a definitive consent statement and accompanying form of consent card to be used in connection with the solicitation of consents from the stockholders of AMAG Pharmaceuticals, Inc . (the “Company”) . All stockholders of the Company are advised to read the definitive consent statement and other documents related to the solicitation of consents by the Participants when they become available, as they will contain important information, including additional information related to the Participants . The definitive consent statement and an accompanying consent card will be furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http : //www . sec . gov/ and at Caligan’s website www . saveamag . com and from the Participants’ consent solicitor, D . F . King & Co . , Inc . by requesting a copy via email to AMAG@dfking . com . Information about the Participants and a description of their direct or indirect interests by security holdings is contained in the Schedule 14 A filed by Caligan with the SEC on September 4 , 2019 . This document is available free of charge from the sources indicated above .

 
 

Exhibit 3

 

Exhibit 4

Item 4. PURPOSE OF TRANSACTION

 

Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following:

 

On September 4, 2019, the Reporting Persons filed a preliminary consent statement (the "Preliminary Consent Statement") in connection with its solicitation of written consents of the Issuer’s stockholders stating, among other things, their intention to solicit stockholders to (i) remove four members of the Board of the Issuer; (ii) elect the following four individuals—Paul Fonteyne, Lisa Gersh, David Johnson and Kenneth Shea (collectively, the "Nominees")—to fill the resulting vacancies; (iii) repeal any provision of the Amended and Restated Bylaws of the Company (the "Bylaws") currently in effect that was not included in the Bylaws filed with the SEC on December 17, 2015; (iv) amend Article 2, Sections 2.2 and 2.3 of the Bylaws to fix the size of the Board at no more than nine members; and (v) amend Article 7, Section 7.1 of the Bylaws to require unanimous Board approval in order for directors to amend the Bylaws.

 

Additionally, the Reporting Persons issued a press release (the "Press Release"), announcing, among other things, their intention to solicit consents to remove and replace members of the Board due to operational, strategic and capital allocation missteps made by the incumbent Board and management of the Issuer. This description of the Press Release is qualified in its entirety by reference to the full text of the Press Release, which is attached hereto as Exhibit B and is incorporated by reference herein. The Reporting Persons have also made available a public presentation to stockholders (the "AMAG Presentation"), stating, among other things, the Reporting Persons’ belief that (i) the Issuer’s Board is in need of immediate refreshment with the Nominees, (ii) post-Board refreshment, the Issuer should initiate a comprehensive strategic review around its asset portfolio, (iii) the Issuer should engage an international distribution partner for Feraheme and (iv) the Issuer should immediately rationalize its commercial spending and explore non-traditional efforts and partnerships to market certain products. The foregoing summary of the AMAG Presentation is qualified in its entirety by reference to the full text of the AMAG Presentation, which is attached hereto as Exhibit C and is incorporated by reference herein.